Inovio Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO Inovio Pharmaceuticals is Jacqueline Shea, benoemd in May2022, heeft een ambtstermijn van 2.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.44M, bestaande uit 30.8% salaris en 69.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.13% van de aandelen van het bedrijf, ter waarde $ 140.99K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.4 jaar en 5.8 jaar.

Belangrijke informatie

Jacqueline Shea

Algemeen directeur

US$2.4m

Totale compensatie

Percentage CEO-salaris	30.8%
Dienstverband CEO	2.5yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	3.4yrs
Gemiddelde ambtstermijn bestuur	5.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Jacqueline Shea's beloning veranderd ten opzichte van Inovio Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$113m
Jun 30 2024	n/a	n/a	-US$122m
Mar 31 2024	n/a	n/a	-US$125m
Dec 31 2023	US$2m	US$751k	-US$135m
Sep 30 2023	n/a	n/a	-US$165m
Jun 30 2023	n/a	n/a	-US$168m
Mar 31 2023	n/a	n/a	-US$241m
Dec 31 2022	US$4m	US$730k	-US$280m
Sep 30 2022	n/a	n/a	-US$332m
Jun 30 2022	n/a	n/a	-US$355m
Mar 31 2022	n/a	n/a	-US$328m
Dec 31 2021	US$2m	US$468k	-US$304m
Sep 30 2021	n/a	n/a	-US$221m
Jun 30 2021	n/a	n/a	-US$142m
Mar 31 2021	n/a	n/a	-US$188m
Dec 31 2020	US$2m	US$431k	-US$166m
Sep 30 2020	n/a	n/a	-US$180m
Jun 30 2020	n/a	n/a	-US$222m
Mar 31 2020	n/a	n/a	-US$123m
Dec 31 2019	US$1m	US$335k	-US$119m

Compensatie versus markt: De totale vergoeding ($USD 2.44M ) Jacqueline } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 359.47K ).

Compensatie versus inkomsten: De vergoeding van Jacqueline is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Jacqueline Shea (58 yo)

2.5yrs

Tenure

US$2,438,908

Compensatie

Dr. Jacqueline E. Shea, Ph D., serves as Chief Executive Officer & President at Inovio Pharmaceuticals, Inc. since May 10, 2022 and serves as its Director since May 16, 2022. Dr. Shea served as Chief Opera...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jacqueline Shea	CEO, President & Director	2.5yrs	US$2.44m	0.13% $ 141.0k
Peter Kies	Chief Financial Officer	22.4yrs	US$1.16m	0.095% $ 103.7k
Laurent Humeau	Chief Scientific Officer & Chairman of the Scientific Advisory Board	5.7yrs	US$1.14m	0.093% $ 102.0k
Thomas Hong	Manager of Investor Relations	no data	geen gegevens	geen gegevens
Robert Crotty	General Counsel & Chief Compliance Officer	3yrs	geen gegevens	geen gegevens
E. Brandreth	Senior Vice President of Quality Assurance	no data	geen gegevens	geen gegevens
Jeffrey Skolnik	Senior Vice President of Clinical Development	4.1yrs	geen gegevens	geen gegevens
Robert Juba	Senior Vice President of Biological Manufacturing & Clinical Supply Management	4.1yrs	geen gegevens	geen gegevens
Shawn Bridy	Senior Vice President of Business Development	3.8yrs	geen gegevens	geen gegevens
David Liebowitz	Senior Vice President of Early-Stage Clinical Development	less than a year	geen gegevens	geen gegevens
Michael Sumner	Chief Medical Officer	2.4yrs	geen gegevens	0.031% $ 34.4k
Cheryl Elder	Senior Vice President of Regulatory Affairs	1.7yrs	geen gegevens	geen gegevens

3.4yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0A43 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jacqueline Shea	CEO, President & Director	2.5yrs	US$2.44m	0.13% $ 141.0k
Laurent Humeau	Chief Scientific Officer & Chairman of the Scientific Advisory Board	less than a year	US$1.14m	0.093% $ 102.0k
Wendy Yarno	Independent Director	6.9yrs	US$123.69k	0.032% $ 35.0k
Lota Zoth	Independent Director	5.8yrs	US$118.69k	0.025% $ 27.5k
Jay Shepard	Independent Director	4.8yrs	US$119.31k	0.027% $ 29.5k
Simon Benito	Independent Chairman of Board of Directors	20.9yrs	US$151.19k	0.038% $ 42.0k
David B. Weiner	Member of the Scientific Advisory Board & Director	8.7yrs	US$201.79k	0.32% $ 345.7k
Stanley Plotkin	Member of Scientific Advisory Board	15.4yrs	geen gegevens	geen gegevens
Ann Miller	Independent Director	5.7yrs	US$126.94k	0.030% $ 32.3k
Roger Dansey	Independent Director	3.5yrs	US$108.69k	0.026% $ 28.3k
Rafi Ahmed	Member of Scientific Advisory Board	6yrs	geen gegevens	geen gegevens

5.8yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0A43 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).

Inovio Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

INOVIO Appointsof Steven Egge as Chief Commercial Officer

Inovio Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

INOVIO Announces Board Changes

High number of new directors

INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel

Inovio Pharmaceuticals, Inc. Announces Changes to Its Board

Recent updates

New major risk - Financial position

Third quarter 2024 earnings released: US$0.89 loss per share (vs US$1.52 loss in 3Q 2023)

Inovio Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 14, 2024

New major risk - Share price stability

Inovio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.

New minor risk - Profitability

Second quarter 2024 earnings released: US$1.19 loss per share (vs US$1.61 loss in 2Q 2023)

Inovio Pharmaceuticals, Inc. Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107

Inovio Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

INOVIO Announces INO-3107 Receives the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway

INOVIO Appointsof Steven Egge as Chief Commercial Officer

New minor risk - Profitability

First quarter 2024 earnings released: US$1.31 loss per share (vs US$1.89 loss in 1Q 2023)

Inovio Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 13, 2024

Inovio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $35.937522 million.

Inovio Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

New minor risk - Profitability

Forecast to breakeven in 2026

Full year 2023 earnings released: US$6.09 loss per share (vs US$14.07 loss in FY 2022)

Inovio Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 06, 2024

New minor risk - Profitability

Forecast to breakeven in 2026

New minor risk - Profitability

Third quarter 2023 earnings released: US$0.13 loss per share (vs US$0.15 loss in 3Q 2022)

Inovio Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Inovio Pharmaceuticals, Inc. Receives FDA Feedback That Data from Completed Phase 1/2 Trial of INO-3107

New minor risk - Market cap size

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.46 loss in 2Q 2022)

Inovio Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) dropped from Russell 2000 Value Index

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.36 loss in 1Q 2022)

INOVIO Presents New Data from A Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

Inovio Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Inovio Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Inovio Reports Positive Phase 1B Results for INO-4201 as an Ebola Booster for rVSV-Zebov (Ervebo®)

Inovio Pharmaceuticals, Inc. Announces Strategic Reorganization and 11% Reduction of Full-Time Employees

Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.29 loss in 3Q 2021)

INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800

Inovio Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 08, 2022

INOVIO Reports Positive Interim Phase 1/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

Second quarter 2022 earnings released: US$0.46 loss per share (vs US$0.39 loss in 2Q 2021)

Inovio Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo(R) (cemiplimab) in Patients with Newly Diagnosed GBM

INOVIO Announces Board Changes

First quarter 2022 earnings released: US$0.36 loss per share (vs US$0.27 loss in 1Q 2021)

No longer forecast to breakeven

No longer forecast to breakeven

Inovio Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 01, 2022

High number of new directors

INOVIO Updates on Phase 3 Program for VGX-3100 for HPV-Associated Cervical High-Grade Squamous Intraepithelial Lesions

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.12 profit in 3Q 2020)

INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico

Forecast to breakeven in 2023

INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its Covid-19 DNA Vaccine Candidate, INO-4800

Second quarter 2021 earnings released: US$0.39 loss per share (vs US$0.83 loss in 2Q 2020)

INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate

INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine against Middle East Respiratory Syndrome, a Coronavirus Disease

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) dropped from Russell 3000 Growth Index

Forecast breakeven pushed back to 2024

Inovio's Pan-Covid-19 Vaccine Candidate (INO-4802) Induces Broad Immunity Against Major Viral Variants in Preclinical Studies

First quarter 2021 earnings released: US$0.27 loss per share (vs US$0.26 loss in 1Q 2020)

INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine

INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel

INOVIO Announces Positive Results from REVEAL 1, Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-Based HPV Immunotherapy for the Treatment of High-Grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18

Full year 2020 earnings released: US$1.07 loss per share (vs US$1.21 loss in FY 2019)

Revenue beats expectations

QIAGEN N.V. and Inovio Pharmaceuticals Announces an Extension of Their Partnership with A New Master Collaboration Agreement to Develop Liquid Biopsy-Based Companion Diagnostic Cervical Dysplasia

INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa